Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: UC - Ulcerative Colitis Clear all
Completed Phase 3 Interventional Results available

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

NCT02522780
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

NCT02914535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis

NCT05180279
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
7-day sleep lab
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

NCT03760003
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
San Diego, California • Decatur, Georgia • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

NCT00577473
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07113522
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Interventions
MT-501, MT-201
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

NCT03298022
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-168
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Newport Beach, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Piloting an Insomnia Treatment in Patients With Ulcerative Colitis

NCT07428629
View directory record Official record
Conditions
Insomnia, Ulcerative Colitis
Interventions
CBT-I UC
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional Results available

A Trial of Yoga in Pediatric Inflammatory Bowel Disease

NCT03338894
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Yoga
Behavioral
Lead sponsor
Atlantic Health System
Other
Eligibility
10 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Morristown, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Melatonin and Ulcerative Colitis: A Pilot Clinical Trial

NCT00790478
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Melatonin, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 69 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

NCT06094608
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Morning light treatment, Treatment-as-usual
Device · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

NCT07224113
View directory record Official record
Conditions
IBD, Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Ultra Processed Food, Nutrition Assessment, DGBI
Interventions
Handout-Only Intervention, Handout + Video Intervention
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting No phase listed Observational

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

NCT07619547
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort

NCT02503514
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohns Disease, Ulcerative Colitis, Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

NCT01124149
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX mesalamine/ mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

NCT03800420
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

NCT01694485
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Abrilumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00487539
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 23, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Fermented Food-Supplemented Diet in Ulcerative Colitis

NCT04401605
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Diet Modification, Ulcerative Colitis
Interventions
Fermented Food-supplemented Diet, Regular Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

NCT00798642
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Hypnotherapy, Standard care, Mind Body Therapy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

NCT04508413
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
KB295
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 23, 2026, 8:59 PM EDT
Active, not recruiting Phase 1 Interventional

Angiographic Delivery of AD-MSC for Ulcerative Colitis

NCT04312113
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adipose derived, autologous mesenchymal stem cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 8:59 PM EDT